ArticleScientific reports2025
Efficacy of imipenem combined with dimercaptosuccinic acid in a murine sepsis model using Pseudomonas aeruginosa.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metallo-β-lactamase-producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors.The Journal of antimicrobial chemotherapy · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Infection with metallo β-lactamase (MBL)-producing Pseudomonas aeruginosa poses a global health challenge due to its multidrug resistance and the paucity of available antibiotic therapies. Because MBL-producing P. aeruginosa requires zinc ions to hydrolyze β-lactams, it is proposed that meso-dimercaptosuccinic acid (DMSA), a heavy metal chelator, may bind to the zinc ions of the MBL active site necessary for its activity. The bactericidal and synergistic activity of imipenem plus DMSA was studied against the PAO1 reference strain of P. aeruginosa and five isogenic PAO1 strains producing the MBLs NDM-1, IMP-1, IMP-10, IMP-13, and VIM-2. The efficacy of imipenem and DMSA alone or in combination was tested in a murine model of peritoneal sepsis. In vitro, combination with DMSA increased the activity of imipenem against all MBL-producing strains and had a synergistic effect. In a murine peritoneal sepsis model, we found that combination with DMSA improved the efficacy of imipenem for NDM-1- and IMP-producers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.